logo

For the Inventor, By the Inventor

Munich, Germany

Hans Thoenen

This inventor holds 6 USPTO granted patents. Top assignees: Regeneron Pharmaceuticals, Inc., Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Other. Active years: 1993-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Thoenen. Retrieved from https://idiyas.com/inventor/hans-thoenen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 4

Forward Citations = 221(Granted Patents)


Location History:

  • Munich 2, DE (1993)
  • Munich, DE (1993 - 2005)

Company Filing History:

goldMedal5 out of 1,482 
 
Regeneron Pharmaceuticals, Inc.
 patents
silverMedal3 out of 1,334 
 
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.
 patents
bronzeMedal1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1993-2005

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6933276 - Methods of treating peripheral neuropathies using neurotrophin-3 (2005-08-23),
2. 6602687 - DNA encoding human ciliary neurotrophic factor and method for producing the protein encoded thereby (2003-08-05),
3. 5453361 - Method for producing biologically active human brain derived (1995-09-26),
4. 5438121 - Brain derived neurotrophic factor (1995-08-01),
5. 5229500 - Brain derived neurotrophic factor (1993-07-20),
6. 5180820 - Brain-derived neurotrophic factor (1993-01-19),

Title: The Innovations of Hans Thoenen

Introduction

Hans Thoenen is a notable inventor based in Munich, Germany. He has made significant contributions to the field of neurobiology, particularly in the development of neurotrophic factors. With a total of 6 patents, his work has paved the way for advancements in the treatment of neurological disorders.

Latest Patents

One of Hans Thoenen's latest patents is focused on methods of treating peripheral neuropathies using neurotrophin-3 (NT-3). This invention relates to NT-3, a newly discovered member of the BDNF gene family. The patent outlines the identification of regions of nucleic acid sequence homology shared by BDNF and NGF, which can be used to identify new members of the BDNF/NGF gene family. The invention provides for the genes and gene products of new BDNF/NGF related neurotrophic factors identified by these methods. NT-3 may be utilized in the diagnosis and treatment of neurologic disorders, including Alzheimer's disease and Parkinson's disease. The unique activity spectrum of NT-3 offers valuable options for inducing regrowth and repair in the central nervous system.

Career Highlights

Throughout his career, Hans Thoenen has worked with prominent organizations such as Regeneron Pharmaceuticals, Inc. and the Max Planck Society for the Advancement of Science. His research has significantly impacted the understanding of neurotrophic factors and their applications in medicine.

Collaborations

Hans Thoenen has collaborated with esteemed colleagues, including Yves-Alain Barde and Friedrich Lottspeich. These partnerships have contributed to the advancement of research in neurobiology and the development of innovative treatments.

Conclusion

Hans Thoenen's contributions to the field of neurobiology through his patents and collaborations have made a lasting impact on the treatment of neurological disorders. His work continues to inspire future innovations in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…